Hansa Biopharma Year-End Report 2018
With positive clinical results from the Company’s lead clinical program, Hansa readies for transition to commercial-stage companyOctober – December 2018 in brief ›› To better reflect its evolution and long-term aspirations, Hansa Medical AB changed its name to Hansa Biopharma AB. The new name represents the next stage in the Company’s lifecycle and emphasizes Hansa’s focus on the development and commercialization of biopharmaceuticals. This refinement of Hansa’s profile is particularly salient as the Company continues the international expansion of its business and investor base. ›› In
